Navigation Links
Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012
Date:10/25/2011

UNION CITY, Calif., Oct. 25, 2011 /PRNewswire/ -- ABAXIS, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the second fiscal quarter ended September 30, 2011.

Record quarterly highlights include:

  • Revenues of $40.0 million, up 13% over last year's comparable quarter.
  • North America revenues of $32.0 million, up 8% over last year's comparable quarter.
  • Veterinary market sales of $31.5 million, up 18% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of $22.8 million, up 18% over last year's comparable quarter.

  • Other quarterly highlights include:

  • Medical market sales of $7.3 million, up 7% over last year's comparable quarter.
  • Total medical and veterinary instrument sales of $8.8 million, up 15% over last year's comparable quarter.
  • Total medical and veterinary instrument sales of 1,227 units, up 24% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of 1.8 million units, up 16% over last year's comparable quarter.

  • Quarterly Results:  For the fiscal quarter ended September 30, 2011, Abaxis reported revenues of $40.0 million, as compared with revenues of $35.3 million for the comparable period last year, an increase of 13 percent.
    Revenues from instruments, which include chemistry analyzers, hematology instruments, VSpro coagulation and specialty analyzers and i-STAT analyzers, increased by an aggregate of $1.1 million, or 15 percent, over the same period last year.  Revenues from consumables, which include reagent discs, hematology reagent kits, VSpro coagulation and specialty cartridges, i-STAT cartridges and rapid tests, increased by an aggregate of $4.2 million, or 17 percent, over the same period last year.
    Abaxis reported net income of $3.3 million for the fiscal quarter ended September 30, 2011, compared to $3.7 million for the same period last year.
    Abaxis' effective tax rate in the quarter ended September 30, 2011 was 37 percent, compared to 39 percent for the same period last year.
    Abaxis reported diluted net income per share of $0.15 (calculated based on 22,564,000 shares) for the three-month period ended September 30, 2011, compared to $0.17 per share (calculated based on 22,691,000 shares) for the same period last year.

    Six-Month Results:  For the six-month period ended September 30, 2011, Abaxis reported revenues of $76.0 million, as compared with revenues of $70.2 million for the comparable period last year, an increase of 8 percent.
    Revenues from instrument sales increased by an aggregate of $1.3 million, or 9 percent, over the same period last year.
    Revenues from consumables increased by an aggregate of $5.6 million, or 11 percent, over the same period last year.
    The company reported net income of $5.5 million, compared to $7.3 million for the same period last year.
    The company's effective tax rate in the six-month period ended September 30, 2011, was 37 percent, compared to 39 percent for the same period last year.  The company reported diluted net income per share of $0.24 (calculated based on 22,850,000 shares) for the six-month period ended September 30, 2011, compared to $0.32 per share (calculated based on 22,736,000 shares) for the same period last year.

    Other Reported Information:  Total sales in the medical market for the second quarter of fiscal 2012 were $7.3 million, an increase of 7 percent, compared to the same period last year.  Medical sales worldwide, excluding sales to the U.S. government, during the second quarter of fiscal 2012 were $6.3 million, an increase of 6 percent, compared to the same period last year.  Total sales in the veterinary market for the second quarter of fiscal 2012 were $31.5 million, an increase of 18 percent, compared to the same period last year.  Veterinary reagent disc sales for the second quarter of fiscal 2012 were $17.6 million, an increase of 18 percent compared to the same period last year.  Non-cash compensation expense recognized for share-based awards during the second quarter of fiscal 2012 was $1.6 million, compared to $1.1 million for the same period last year.  Cash, cash equivalents and investments decreased during the second quarter of fiscal 2012 by $24.2 million due to our stock repurchase program.  Costs related to development of our full service commercial laboratory for veterinarians, Abaxis Veterinary Reference Laboratories (AVRL), during the three and six months ended September 30, 2011, were $1.1 million and $1.6 million, respectively.

    "This was a very solid quarter for Abaxis," commented Clint Severson, chairman and chief executive officer of Abaxis.  "We achieved record revenues for the quarter exceeding $40.0 million, total instrument sales in units grew 24%, total reagent disc sales increased 18%, and we experienced solid international sales growth, approaching 40%.  We were particularly pleased with the growth in sales in Europe and Asia; which we believe bodes well for the future.  Our markets, by and large, appear to be very strong at the moment.  While we still have work to do in accelerating medical instrument sales, we are confident in the accuracy and reliability of our Piccolo medical instrument and of our ability to gain market share going forward.  We are very pleased with the results of the second quarter."

    Mr. Severson continued, "On another front, in our second quarter of fiscal 2012, AVRL went live with our partners at Kansas State University.  We have completed the bulk of the initial investment to get this venture operational and we look forward to serving the veterinary community nationwide with our leading-edge technology and customer service.  Over the past 16 years we have built a high level of credibility with the segment of the veterinary community that relies on our point-of-care instruments to compassionately care for their patients on a timely basis.  We believe that this community will give AVRL the opportunity to earn their reference laboratory business.  Our expectation is to leverage that credibility and develop a consistently growing business in the years to come."

    "We are also devoted to enhancing the market capitalization of the company for the benefit of our loyal shareholders.  The Board has authorized us to acquire up to $40.0 million of Abaxis common stock in the open market.  In our second quarter of fiscal 2012, we acquired approximately 1.2 million shares in the open market for approximately $27.3 million.  We believe this is a sound investment and we will take the opportunity to support our shareholders in the future when we believe the price is appropriate.  We are very upbeat about the prospects of the company in the coming years."

    Conference CallAbaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Tuesday, October 25, 2011.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call will be available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10005496, through November 1, 2011.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.  

    About AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus and Giardia.  Abaxis, through its AVRL Division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.  This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).

    Use of Financial MeasuresTo supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure.  The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.  For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release.  Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

    This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products, the continuing development of its products and the Abaxis Veterinary Reference Laboratories, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Financial Tables on Following PagesABAXIS, INC.Condensed Consolidated Statements of Income(In thousands, except per share data)(Unaudited)Three Months EndedSix Months EndedSeptember 30,September 30,2011201020112010Revenues

    $
    40,025

    $
    35,277

    $
    76,028

    $
    70,230Cost of revenues

    18,004

    15,527

    34,784

    30,696Gross profit

    22,021

    19,750

    41,244

    39,534Operating expenses:   Research and development

    3,008

    3,296

    6,462

    6,374   Sales and marketing

    9,335

    8,408

    18,487

    17,041   General and administrative

    4,495

    2,652

    7,914

    4,776Total operating expenses

    16,838

    14,356

    32,863

    28,191Income from operations

    5,183

    5,394

    8,381

    11,343Interest and other income (expense), net

    56

    757

    350

    652Income before income tax provision

    5,239

    6,151

    8,731

    11,995Income tax provision

    1,918

    2,402

    3,196

    4,666Net income

    $
    3,321

    $
    3,749

    $
    5,535

    $
    7,329Net income per share:  Basic net income per share

    $
    .15

    $
    .17

    $
    .25

    $
    .33  Diluted net income per share

    $
    .15

    $
    .17

    $
    .24

    $
    .32Shares used in the calculation of net income per share:  Weighted average common shares outstanding - basic

    22,290

    22,317

    22,484

    22,264  Weighted average common shares outstanding - diluted

    22,564

    22,691

    22,850

    22,736ABAXIS, INC.Condensed Consolidated Balance Sheets(Unaudited and in thousands)September 30,March 31,20112011Current assets: Cash and cash equivalents

    $
    37,994

    $
    43,471 Short-term investments

    17,649

    25,981 Receivables, net

    27,490

    27,880 Inventories

    19,109

    19,814 Prepaid expenses and other current assets

    5,068

    3,496 Net deferred tax assets, current

    3,048

    3,422   Total current assets

    110,358

    124,064 Long-term investments

    29,099

    36,237 Investment in unconsolidated affiliate

    2,697

    2,769 Property and equipment, net

    22,913

    19,637 Intangible assets, net

    3,919

    4,216 Net deferred tax assets, non-current

    1,203

    1,203 Other assets

    111

    134Total assets

    $
    70,300

    $
    88,260Current liabilities: Accounts payable

    $
    ,996

    $
    ,173 Accrued payroll and related expenses

    6,873

    6,129 Accrued taxes

    232

    559 Other accrued liabilities

    1,788

    1,677 Deferred revenue

    1,103

    953 Warranty reserve

    1,123

    1,031   Total current liabilities

    18,115

    16,522Non-current liabilities: Deferred rent

    530

    416 Deferred revenue

    2,105

    1,737 Warranty reserve

    313

    191 Notes payable, less current portion

    834

    746   Total non-current liabilities

    3,782

    3,090   Total liabilities

    21,897

    19,612Shareholders' equity: Common stock

    106,262

    132,042 Retained earnings

    42,141

    36,606   Total shareholders' equity

    148,403

    168,648   Total liabilities and shareholders' equity

    $
    70,300

    $
    88,260Operating Income Per Share(In thousands, except per share data)Three Months EndedSix Months EndedSeptember 30,September 30,2011201020112010Shares used in the calculation of operating income per share:  Weighted average common shares outstanding - basic

    22,290

    22,317

    22,484

    22,264  Weighted average common shares outstanding - diluted

    22,564

    22,691

    22,850

    22,736Operating income per share - basic

    $
    .23

    $
    .24

    $
    .37

    $
    .51Operating income per share - diluted

    $
    .23

    $
    .24

    $
    .37

    $
    .50Revenues by Geographic Region(In thousands)Three Months EndedSix Months EndedSeptember 30,September 30,2011201020112010North America

    $
    31,985

    $
    29,528

    $
    ,693

    $
    57,317International

    8,040

    5,749

    14,335

    12,913Total revenues

    $
    40,025

    $
    35,277

    $
    76,028

    $
    70,230Revenues by Customer Group(In thousands)Three Months EndedSix Months EndedSeptember 30,September 30,2011201020112010Medical Market

    $
    7,333

    $
    ,857

    $
    4,489

    $
    3,295Veterinary Market

    31,548

    26,649

    59,217

    53,467Other

    1,144

    1,771

    2,322

    3,468Total revenues

    $
    40,025

    $
    35,277

    $
    76,028

    $
    70,230
    '/>"/>

    SOURCE ABAXIS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011
    2. Abaxis, Inc. to Present at CL Kings 9th Annual Best Ideas Conference 2011
    3. Abaxis to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference
    4. Abaxis Announces Stock Repurchase Program
    5. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
    6. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
    7. Abaxis to Present at Jefferies 2011 Global Healthcare Conference
    8. Abaxis to Present at ThinkEquitys Second Annual Healthcare Conference
    9. Abaxis Receives Presidential "E" Award for Exports
    10. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
    11. Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... Calif. , Feb. 12, 2016  SI-BONE, Inc., a medical ... ® ("iFuse"), a minimally invasive surgical (MIS) device indicated for ... National Government Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering ... , Maine , Massachusetts ... , New York , Rhode Island ...
    (Date:2/12/2016)... , Feb. 12, 2016  Sequent Medical, Inc. ... a study to evaluate the safety and effectiveness of ... treatment of ruptured intracranial aneurysms.  Prof Laurent Spelle ... in Paris, France and Principal ... France and Germany.  Although ...
    (Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
    Breaking Medicine Technology:
    (Date:2/13/2016)... ... ... Cypress in Sun City is the place to be on March 3rd to learn about ... will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will ... offers. In addition, prizes will be given away and light refreshments will be served. ...
    (Date:2/13/2016)... ... February 13, 2016 , ... ... Voices of Recovery, the leading national organization representing the growing community of recovering ... public office to include Family Recovery in policies addressing addiction. , Although ...
    (Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from ... all within Final Cut Pro X. Each user can select from up to 40 ... of view, blur, focus offset, hue, saturation, value, contrast, glow, and more all within ...
    (Date:2/13/2016)... , ... February 13, 2016 , ... ... Nurses Society (INS) states that vein visualization technology should be used to ensure ... facilities around the world, the INS Standards mandate the use of vein visualization ...
    (Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
    Breaking Medicine News(10 mins):